Business Context and Reporting Period
This Form 8-K was filed by Pluristem Therapeutics Inc. on June 20, 2011, reporting an event that occurred on June 19, 2011. The registrant's wholly owned Israeli subsidiary, Pluristem Ltd., entered into an Exclusive License Agreement with United Therapeutics Corporation.
Key Financial Metrics and Agreement Terms
The filing details a strategic partnership rather than historical financial performance. Key financial terms of the agreement include:
- Total Potential Payments: Up to approximately $55 million.
- Upfront Payment: $7 million payable within 15 days of the Effective Date.
- Regulatory Milestones: Up to $37.5 million upon reaching certain regulatory milestones.
- Manufacturing Facility: Shared costs for a North American facility following a successful Phase II trial, with United Therapeutics committing up to $10 million.
- Ongoing Revenue: Commercial supply purchases at a specified margin over cost and royalties based on gross profits.
The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures for the company.
Material Changes and Conditions
The primary material change is the execution of the Exclusive License Agreement for the development and commercialization of a cell-based product (PLX cells) for the treatment of Pulmonary Hypertension. The agreement grants United Therapeutics exclusive worldwide license rights in this field. A critical condition precedent is the consent of the Office of Chief Scientist in Israel; the agreement becomes effective only upon receipt of this consent. If consent is not obtained within 60 days of the agreement date, the agreement will terminate absent a waiver.
Outlook, Risks, and Contingencies
Management commentary is limited to a Safe Harbor Statement regarding forward-looking statements. Key risks and contingencies identified include:
- Regulatory Approval: Failure to obtain required regulatory approval is a condition to closing and future payments.
- Scientific Validation: Technology may not be validated, or laboratory results may not translate to real surgical settings.
- Operational Risks: Potential delays in clinical trials, inability to retain key employees, and unforeseen scientific difficulties.
- Market Risks: Changes in legislation, competition, and pricing pressure.
- Guarantees: The registrant has unconditionally guaranteed the obligations and liabilities of Pluristem Ltd. under the agreement.
Investor Verification Checklist
- Confirm whether the Office of Chief Scientist in Israel has granted the required consent to make the agreement effective.
- Verify the specific regulatory milestones required to trigger the $37.5 million in milestone payments.
- Review the defined "specified margin" for commercial supply purchases and the royalty percentage structure.
- Assess the company's current cash position to determine if the $7 million upfront payment is critical for liquidity.
- Monitor the status of the Phase II clinical trial required to trigger the shared manufacturing facility costs.